GlaxoSmithKline and the University of Texas MD Anderson Cancer Center, through its Moon Shots Program, have entered into a research-and-development collaboration centered on cancer immunotherapies. The partners agreed to look for new therapeutic approaches, assess patient responses in clinical trials and develop immunotherapy drugs using insights gained from the partnership. "This collaboration brings together MD Anderson's basic science capabilities with GSK's drug discovery and development expertise, and our growing immuno-oncology portfolio," said Axel Hoos, GSK's vice president for oncology R&D.

Related Summaries